title: Biologics in dermatology: adverse effects.
abstract: Biologics are a group of drugs that precisely affect certain specific steps in the immune response and are an extremely useful group when used in an appropriate setting. However, their use can often be a double-edged sword. Careful patient selection and thorough knowledge of adverse effects is a key to their successful use in various disorders. The initial enthusiasm has gradually given way to a more cautious approach wherein a balance is sought between clinical usefulness and expected side effects. The adverse effects of the biologics most commonly used in dermatology have been carefully listed for ready reference. The plausible causes of the adverse reactions are succinctly outlined along with their incriminating factor(s). Besides, in brief, the attention has been focused on their management. The content should provide an essential didactic content for educating the practitioner.
authors.affiliation: Dermato-Venereology (Skin/VD) Center, Sehgal Nursing Home, Delhi, India.
authors.forename: Virendra N
authors.initials: VN
authors.lastname: Sehgal
authors.affiliation: Department of Dermatology and STD, University College of Medical Sciences, and Associated Guru Teg Bahadur Hospital, Shahdara, Delhi, India.
authors.forename: Deepika
authors.initials: D
authors.lastname: Pandhi
authors.affiliation: Department of Dermatology and STD, Dr RML hospital and PGIMER, New Delhi, India.
authors.forename: Ananta
authors.initials: A
authors.lastname: Khurana
mesh_terms: D000068879:Adalimumab / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D001688:Biological Products / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D000068582:Certolizumab Pegol / Q000009:adverse effects; D003879:Dermatologic Agents / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D003875:Drug Eruptions / Q000209:etiology; D000068800:Etanercept / Q000009:adverse effects; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects; D007155:Immunologic Factors / Q000009:adverse effects; D007239:Infections / Q000139:chemically induced*; D000069285:Infliximab / Q000009:adverse effects; D007267:Injections / Q000009:adverse effects; D009369:Neoplasms / Q000139:chemically induced*; D000069283:Rituximab / Q000009:adverse effects; D012871:Skin Diseases / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D000069549:Ustekinumab / Q000009:adverse effects
chemical_list: D000911:Antibodies, Monoclonal; D001688:Biological Products; D003879:Dermatologic Agents; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab; C529000:golimumab; D000069285:Infliximab; D000069549:Ustekinumab; D000068879:Adalimumab; D000068800:Etanercept; D000068582:Certolizumab Pegol